跳至主要内容

Drug Metabolism and Pharmacokinetics (DMPK) CRO

DMPK  or Drug Metabolism and Pharmacokinetics is a major part of studies related to drugs often referred to as ADME (Absorption, Distribution, Metabolism and Elimination). It is concerned with the study of aspects of absorption, distribution, metabolism and elimination of drug compounds which are administered through any route of administration.

Drug Metabolism and Pharmacokinetics(DMPK) cro

Drug Metabolish and Pharmacokinetics are specific to drug discovery; drug properties such as route of administration, dose level, dose regimen and formulation, drug-drug interactions and specific populations are all tightly related to DMPK and are therefore measured by our experts. Our DMPK Department is dedicated to the understanding of the absorption, distribution, metabolism and excretion of drug candidates.

Medicilon’s Pharmacokinetics Services

Medicilon’s pharmacokinetics department offers the clients a broad spectrum of high quality of services in the areas of in vitro ADME, in vivo pharmacokinetics and bioanalysis services, ranging from small molecules to large molecules, such as protein and antibody. The animal species involved in our DMPK cro services are non-human primate, canine, mice, rat, rabbit and hamster. Meanwhile, non-human primate experimental platform and isotope platform for protein/antibody are certified by the Shanghai Government.

Available studies include:

  • Method development and validation (GLP & Non-GLP) 
  • Bioanalysis 
  • Pharmacokinetics (Tumor bearing rodents, Bioavailability, Crossover studies,  Cassette (N in 1) dosing and analysis, effects of gender on pharmacokinetics, BBB  penetration ) 
  • Stability in vehicles and plasma 
  • Drug interaction studies
  • In vitro metabolic stability
  • Prediction and identification of major metabolites
  • Toxicokinetics analysis
  • Distribution studies

Pharmacokinetics Package for IND Filing

DMPK package for CFDA and FDA IND filing

  • Chemical Compounds
  • Traditional Chinese Medicine
  • Protein
  • Antibody

Metabolic Stability Services

  • CYP Reaction Phenotyping
  • Microsomal Stability
  • S9 Stability
  • Hepatocyte Stability
  • Plasma Stability
  • Metabolite Profiling & Identification

Drug-Drug Interaction Services

  • Cytochrome P450 and UGT Reaction Phenotyping
  • Hepatocyte Induction
  • Cytochrome P450 Inhibition
  • Time Dependent Inhibition (Single Point)

Permeability and Transporter Services

  • Caco-2 Permeability
  • P-gp Inhibition

DMPK: Available reaction phenotyping services include:

  • Phase I:
  • Cytochrome P450 Enzymes (CYP)
  • Phase II:
  • UDP-glucuronyltransferases (UGT)

Metabolic Stability

  • Microsomes stability
  • Hepatocytes stability
  • Plasma stability
  • S9 stability

Protein Binding Services

  • Plasma Protein Binding
  • Brain Tissue Binding
  • Whole Blood Binding
  • Blood to Plasma Ratio

In vitro DMPK
High quality ADME data is essential to identify and help to address issues rapidly and early in the drug discovery, lead validation and optimization processes. The in vitro ADME service offers a portfolio of assays for investigating physicochemical properties, permeability, metabolism, drug-drug interactions (CYP inhibition, induction and phenotyping) and protein binding. These assays are offered either as a standalone services or to support our client sponsored medicinal chemistry programs.

In Vivo Pharmacokinetics
We can perform in vivo animal pharmacokinetic (PK) and other ADME studies in mice and rats in our CPCSEA approved AAALAC-accredited animal facility. We have a third party collaboration (CPCSEA approved facility) to perform pharmacokinetic studies in dogs.

A quantitative measure of drug exposure is necessary in order to interpret preclinical efficacy and toxicity studies. In a typical animal PK study, blood samples are obtained from animals at different time points following a single dose of a test compound. Plasma is harvested and subjected to bioanalysis. In an absolute bioavailability study of an orally administered drug, both oral and IV PK has to be performed. Relative oral bioavailability studies with different formulations can be carried out to enable selection of appropriate preclinical formulation for any compound. In toxicology studies, a satellite toxicokinetics group is included so as to assess the NOAEL (No Observable Adverse Effect Level) for any compound.

Contact Us

Email : marketing@medicilon.com

Tel : +86 021 58591500

Tips : Above is part of Drug Metabolism and Pharmacokinetics , DMPK cro studies , DMPK assays. You can also CONTACT US with any question or enquiry you may have. We will be happy to discuss your needs in detail and design an appropriate plan of action.

Related Articles:

ADME Pharmacokinetics Studies

Medicilon Drug Metabolite Analysis Service

Factors Affecting Pharmacokinetics of Drugs

In Vitro Drug Metabolism Studies Services

Drug Metabolism Test of Medicilon

Medicilon’s Drug ADME/PK Assays Services

Pharmacokinetic Research Services

评论

此博客中的热门博文

What is preclinical testing?

In the process of  preclinical testing  of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a  preclinical research  phase followed, before which, as described above, the potential toxicity of the compou

Inventory of the three major in vitro pharmacokinetic research methods

  The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in  Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati